Skip to main content
. 2022 Jul 30;14(8):1589. doi: 10.3390/pharmaceutics14081589

Figure 5.

Figure 5

Schematic of SRNs for cancer immunotherapy. (A) Schematic of the structure of two prodrugs and the pH-responsive behavior for sequential drug release. (B) Schematic of sequential activation mechanisms of immune response after peritumoral injection with SRNs in the tumor-bearing mice. (C) Representative images of tumor tissues at 2 and 12 h after peritumoral injection with SRNs. (D) Representative images of lymph nodes tissues at 12 and 48 h after peritumoral injection with SRNs. (E) Expression levels of CD80 and CD86 on DCs after treatment of SRNs. Reprinted with permission from ref. [143]. Copyright 2021, copyright American Chemical Society.